2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 1
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Breast Neoplasms
3116
Neoplasms
2459
Carcinoma, Non-Small-Cell Lung
1858
Prostatic Neoplasms
1623
Colorectal Neoplasms
1401
Lung Neoplasms
1293
Multiple Myeloma
930
Neoplasm Metastasis
919
Leukemia, Myeloid, Acute
879
Pancreatic Neoplasms
853
Ovarian Neoplasms
800
Melanoma
782
Carcinoma, Hepatocellular
733
Stomach Neoplasms
647
Squamous Cell Carcinoma of Head and Neck
635
Recurrence
635
Brain Neoplasms
624
Head and Neck Neoplasms
598
Glioblastoma
558
Lymphoma
549
Uterine Cervical Neoplasms
535
Triple Negative Breast Neoplasms
511
Precursor Cell Lymphoblastic Leukemia-Lymphoma
509
Carcinoma, Renal Cell
501
Hematologic Neoplasms
464
Urinary Bladder Neoplasms
460
Endometrial Neoplasms
457
Colonic Neoplasms
445
Sarcoma
433
Lymphoma, Non-Hodgkin
432
Interventions
vistusertib
1
olaparib
1
durvalumab
1
danvatirsen
1
adavosertib
1
Neoadjuvant Therapy
1
Cystectomy
1
AZD4547
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Muscle Invasive Bladder Cancer
×
1 year
×
Clear all
NCT02546661
2025-12-29
BISCAY
AstraZeneca
Phase 1
Active not recruiting
117 enrolled
NCT07202819
2025-10-02
"NAC-MRI"
Assiut University
Phase NA
Recruiting
76 enrolled